Phase 3 Randomized, Placebo-controlled, Double-blind Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low-volume Metastatic Hormone-sensitive Prostate Cancer (mHSPC) – Aragon/Janssen 56021927PCR3002(TITAN), NCT02489318
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.
MORE DETAILS ON THIS PROSTATE CANCER TRIAL:
14223 / NCT02489318 / STAR trial / PI TDB
TRIAL AVAILABLE AT THESE LOCATIONS
This is a STAR trial available at any RMCC Location as Patients are identified.